Maziar Mike Doustdar

Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

5 days ago talkbio0Tagged CEO, competition, Drops - Drug Form, drug market, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Prices, Regulatory Affairs, Shakeup, SmithKline Beecham, United States Food and Drug Administration

Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA

Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance

1 week ago talkbio0Tagged CEO, Changing, drug competition, growth outlook, guidance cut, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Sales - occupational activity, Transition Mutation

Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition

Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges

1 week ago talkbio0Tagged Appointments, CEO, Drug Industry, drug market, growth outlook, international operations, Leadership Change, Maziar Mike Doustdar, Nordisk, Obesity

Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations